Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Mechanisms and Therapeutic Perspectives of Chemotherapy-Induced Peripheral Neuropathy: An Update

Version 1 : Received: 5 May 2022 / Approved: 6 May 2022 / Online: 6 May 2022 (09:14:17 CEST)

How to cite: Avallone, A.; Bimonte, S.; Cardone, C.; Forte, C.A.; Cascella, M.; Cuomo, A. Mechanisms and Therapeutic Perspectives of Chemotherapy-Induced Peripheral Neuropathy: An Update. Preprints 2022, 2022050068 (doi: 10.20944/preprints202205.0068.v1). Avallone, A.; Bimonte, S.; Cardone, C.; Forte, C.A.; Cascella, M.; Cuomo, A. Mechanisms and Therapeutic Perspectives of Chemotherapy-Induced Peripheral Neuropathy: An Update. Preprints 2022, 2022050068 (doi: 10.20944/preprints202205.0068.v1).

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) develops as a challenging nerve-damaging adverse effect of anticancer drugs used in chemotherapy. The disorder may require a dose reduction of chemo-therapy and its most common sensory symptoms are severe pain, tingling, and numbness in the hands and feet. CIPN affects dramatically the patient's quality of life (QoL). Pain and sensory abnormalities may occur for months, or even years after the termination of chemotherapy. This disease has complicated pathophysiology featured by underlying mechanisms not completely known. Although many pharmaco-logical and non-pharmacological therapeutic approaches have been tested to overcome these symptoms, there is currently no standardized cure to prevent or treat CIPN. According to current guidelines, Duloxe-tine is the only recommended agent for painful neuropathic symptoms. Therefore, finding effective thera-pies for CIPN is mandatory. The purpose of this review is to dissect CIPN, the target and immunothera-py-based approaches to this disorder, as well as to offer new insights for novel therapeutic perspectives.

Keywords

Chemotherapy-induced peripheral neuropathy; pain management; target therapy; immuno-therapy

Subject

MEDICINE & PHARMACOLOGY, Oncology & Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.